Ottawa Heart Institute Research Corporation
ottawaheart.caTotal trials
180
Active
60
Phase 3
30
Total enrollment
85,153
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 20 of 20 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Normal Saline | — | — | — | 3 | |||
| Dobutamine | — | — | — | — | — | 2 | |
| Milrinone | — | — | — | — | — | 2 | |
| Varenicline | — | — | — | — | — | 2 | |
| Genotyping guided therapy for anti-platelet management | — | — | — | — | — | 1 | |
| Nicotine Replacement Therapy | — | — | — | — | — | 1 | |
| Cytisine | — | — | — | — | 2 | ||
| Dexmedetomidine | — | — | — | — | 2 | ||
| Clopidogrel | — | — | — | — | 4 | ||
| aspirin | — | — | — | — | — | 2 | |
| Dapagliflozin | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Nicotine replacement | — | — | — | — | — | 1 | |
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Midodrine Oral | — | — | — | — | — | 1 | |
| Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] | — | — | — | — | — | 1 | |
| Canagliflozin | — | — | — | — | — | 1 | |
| Prednisone or Prednisolone | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Rb-82 Radioisotope | — | — | — | — | — | 1 |
Next readouts
- 2026-07
- 2026-12
- 2026-12
- 2026-12
- 2026-12-31
- 2026-12-31
- 2027-03
- 2027-04-30
- 2027-05-08
- 2027-06
Top conditions
- Coronary Artery Disease31
- Atrial Fibrillation19
- Heart Failure15
- Cardiovascular Diseases10
- Acute Coronary Syndrome10
- Coronary Heart Disease9
- Smoking Cessation8
- Stroke5
Frequently asked questions about Ottawa Heart Institute Research Corporation
- How many clinical trials does Ottawa Heart Institute Research Corporation have on ClinicalTrials.gov?
- Ottawa Heart Institute Research Corporation is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 60 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ottawa Heart Institute Research Corporation's trials are in Phase 3?
- 30 of Ottawa Heart Institute Research Corporation's trials are in Phase 3, spread across 20 active drug programs.
- What therapeutic areas does Ottawa Heart Institute Research Corporation focus on?
- Ottawa Heart Institute Research Corporation's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Atrial Fibrillation, Heart Failure, Cardiovascular Diseases, Acute Coronary Syndrome.
- When are Ottawa Heart Institute Research Corporation's next clinical trial readouts?
- Ottawa Heart Institute Research Corporation has 10 upcoming primary-completion readouts tracked here; the soonest is “Semaglutide for Smoking Cessation in Patients With Diabetes”, expected around 2026-07.